

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance

Sanchita Roy Pradhan, Sutapa Mahata, Dipanwita Ghosh, Pranab Kumar Sahoo, Sinjini Sarkar, Ranita Pal and Vilas D. Nasare

Abstract

Young women are at the maximum risk of Human papillomavirus (HPV) infection which are asymptomatic in a majority of cases and spontaneously get cleared. Women in the age between 20 and 35 years are more active sexually and especially in the developing nations, this age group forms a major cohort among the population of pregnant women. The changed hormonal *milieu* and immune response during pregnancy might favor presence or persistence of HPV infection, while at the same time natural clearance also takes place during pregnancy with an unknown mechanism. Various HPVs have been reported to be associated with preterm rupture of membranes (PROM), fetal growth restriction (FGR), preeclampsia, placental abnormalities and preterm delivery in several populations. The risk factors involved in the intrauterine environment affects fetal development and thus increase the development risk of specific diseases in adult life as per the hypothesis of the fetal origins of adult disease (FOAD). The structural and molecular changes in the feto-maternal interface support and protect the semiallogeneic fetus from immune-mediated or inflammatory injury. On the other hand, the trophoblast cells of placenta facilitate the replication of HPV and the affliction of placenta and the vaginal infection can directly be associated with pregnancy outcomes. So, to optimize better child health care and reproductive outcomes, HPV screening might help during pregnancy. It is therefore important to understand how the HPV is affecting the early pregnancy and immune cells within the feto-maternal interface are educated for self-clearance to fulfill their biological functions or prevalence to affect the pregnancy outcomes and how the persistence of HR-HPV infection overtime increases the development of cervical cancer risk.

Keywords: pregnancy, self clearance, feto-maternal cell trafficking, HPV vaccine, cervical cancer

1. Introduction

The most common sexually transmitted infectious conditions across the globe are Human papillomavirus (HPV) infections which is responsible for the

development of cervical cancer. The infection of HPV does not always lead towards the neoplastic disease which suggests that the clearance or acquisition of HPV infections may depend on the interpersonal variations in the immune system as well as environmental or viral factors. For example, a well-established cervical cancer risk factor is parity. However, the influence of pregnancy in the natural history of HPV infection and thus the development of cervical neoplasia and its exact mechanism is not known [1].

At the beginning of the pregnancy, immune modulation and induction of tolerance are required for successful implantation allowance but as the pregnancy progresses a responsive immune system is responsible for a successful pregnancy which can protect both the fetus and the mother against environmental insults whenever there is a necessity arises. Indeed the maternal immune system reinforces networks that can respond according to the recognized danger signals and eliminate them appropriately promoting repair when needed. Not only the maternal immune system but also the actively developing immune system in the fetal-placental unit can modify further the maternal immune response and the reaction of the maternal immune system to the environment. So, the immunity during pregnancy is dynamic and unique which can be modulated as per the requirement and definitely not suppressed [2].

Several studies have proven the idea incorrect that constant immunosuppression is crucial for a successful pregnancy which demonstrates that inhibition of key signaling pathways such as pathways mediated by FAS; FAS ligand and deletion of immune cells at the implantation site are detrimental to pregnancy which may lead to pregnancy loss [3, 4]. The deletion of specific decidual NK cells leads to poor endometrial vascularity and obstruct the invasion of the trophoblast [5]. Thus, for a successful pregnancy the presence of immune infiltrates is required which suggests that the immune cells are not recruited to the decidua as a response to a 'non-self' or 'foreign' fetus but recruited actively to facilitate proper implantation and promote successful pregnancy.

During pregnancy and postpartum, different levels of hormonal changes and changes in the immunity may be responsible for the modulation of the natural history of the HPV infection. There are differences in the status of HPV infection during pregnancy and reduction in the number of HPV positive cases during postpartum period have been reported by various authors [6]. Though the dynamics of HPV infection during pregnancy is not well understood and the information remains controversial. The clearance and persistence of HPV during and after pregnancy have been studied by very few authors [7].

HPV infection in most cases naturally disappears in a short relative time period and risk of disease development in that case is very less. As pregnancy affects the host immune system, it is believed that pregnancy reduces the seroreactivity against infection of HPV. The upstream regulatory region of HPV18 has been reported to be activated by estrogen and progesterone which alters the clearance rate of HPV compared to non-pregnant women [8]. HPV genotypes and viral characteristics such as population distribution and evasive ability play an important role during persistent infection. However, how the HPV genotype specific reaction of the host immune system and the sexual behavior of pregnant women affect the rates of infection in case of persistent cases and how it is related to the host is not clear [9].

In pregnancy, the pregnant mother which is an adult organism is exposed to the fetus which is partly an extremely young organism and this phenomenon can be viewed similar to a natural state known as parabiosis in which organisms share partly blood systems. However, the fetus may have restoring effect on the maternal system. It has been reported that the regenerative capacity of the aged liver and other organs in mice model is restored by pregnancy [10].

There are controversial results on the risk of HPV infection in pregnant women. A higher HPV prevalence has been reported in few studies in pregnant women, whereas, some claimed there are no statistical difference among the age matched non-pregnant women [9]. Moreover, there are no studies on estimating the trimester, age and type specific prevalence of cervical HPV DNA in pregnant women.

This chapter will focus on the incidence of HPV infection in pregnant women population, the reason behind higher incidence rates in early pregnancy, the possible mechanisms responsible for self-clearance and non-clearance of HPV in pregnant women, immune mechanisms playing role in pregnancy, feto-maternal cell trafficking and how HPV affects the pregnancy outcomes. Furthermore, we will also discuss the potential of HPV infection during pregnancy can lead to the development of cervical cancer and therapeutic strategies.

2. Incidence of HPV infection in pregnant women population

Highest incidence rates have been reported in young adults just after the onset of their sexual activity [11]. In young women between the age group of 17 and 24 years, longitudinal studies reported incidence rates of HPV infection ranging from 15.7 to 29.4 of all types per 1000 women-months [12]. Women in their thirties showed a lower incidence rate in cohort studies which is between 5.2 and 13.4 any type HPV infection per 1000 women-months [12]. The prevalence is likewise higher in younger age groups than older. The global HPV prevalence estimated by a multi-country meta-analysis is 11.7% (with confidence interval 95% 11.6–11.7%) with normal cytology in women with an important variation within and between geographic regions. At round 25 years the prevalence peaks and decreases thereafter. It has been reported that at around 45 years a smaller second peak is observed [13, 14]. It has also been reported in various studies that within 1–2 years of HPV infection almost 80% of them resolve spontaneously [15]. Various studies suggested that during pregnancy it is more likely to acquire and progress HPV infection [16] which regresses after delivery [6, 7, 17, 18].

Whereas, Liu et al. [16] reported that in pregnant women the HPV prevalence varies from 9.58 to 46.67% and in age-matched non-pregnant women the prevalence varies from 8.9 to 23.5%, with a summary estimate of 16.82 and 12.25% respectively and there are significant differences between the summary estimates. In Asia, North America and Europe, it has been reported that the HPV prevalence rates are significantly higher in pregnant women as compared to those in non-pregnant women and the pregnant women in North America as compared to those in Europe and Asia are more susceptible to HPV infection [16]. As per the meta-analytical data showed by Liu et al. [16], the prevalence rates of HPV infection in pregnant women in North America, Australia, Europe and Asia were 30.37, 36.60, 13.19 and 15.72% respectively which showed a worldwide significant difference. In pregnant women aged 25, 25–29 and ≥ 30 years the prevalence rates of HPV infection were 23.94, 13.34 and 14.79% respectively and in non-pregnant women the prevalence rates were 18, 12.08 and 11.43% in respective three age groups [16]. The most frequently identified HPV types in pregnant women have been reported are HPV-16 with 3.86% prevalence rate, HPV-6 with 2.45% prevalence rate, HPV-18 with 1.80% prevalence rate and HPV-11 with 1.76% prevalence rate which is as same as the prevalence rates in non-pregnant women of these HPV types. In the three trimesters the HPV prevalence rates reported are 18.20, 14.38 and 19.32% and the odd ratios are 1.59, 1.20 and 1.71 respectively as compared to the non-pregnant women population.

Studies conducted in Hong Kong and Hungary showed that in asymptomatic pregnant women HPV-16 is the most common type and HPV-6, -18, -11, -58, -31 and -33 are the other common HPV types [19]. Whereas, in non-pregnant women the sequence is bit different such as HPV-16, -6, -11, -18, -58, -33 and -31 and in women with normal cytology worldwide the sequence reported is HPV-16, -18, -31, -58 and -52 [16].

Specific to genital tract infections, HPV types are classified into three risk categories based on their relative malignant potential such as HPV-6, -11, -40, -42, -43, -44 are low risk; HPV-31, -33, -35, -51, -52 are intermediate and HPV-16, -18, -45, -56 are high risk types. Young women between the ages of 10 and 35 years are reported to be at the maximum risk of HPV infection which are asymptomatic in majority of the cases and spontaneously get cleared may be due to the strong immune system. The reason being this is the age when women are sexually more active. A major cohort of the pregnant population is formed by this age group in the developing nations. The changed immune response and hormonal *milieu* during pregnancy might favor the presence or persistence of the HPV infection. Niyibizi et al. [18] reported the prevalence of HPV infection in pregnant women with a wide variation from 5.5 to 65%. Various HPVs in several populations have been reported to be associated with adverse pregnancy outcomes such as preeclampsia, preterm rupture of membranes (PROM), preterm delivery, fetal growth restriction and placental abnormalities. However, no such data on the association of the HPV infection in pregnancy and its outcome from the Indian subcontinent is available till date [20].

3. The reason behind higher incidence rates in early pregnancy

3.1 Maternal immunity during pregnancy

Starting at the conception and towards the course of completion with labor and birth enormous transformations the uterus has to undergo in pregnancy. In order to achieve blastocyst stage embryo development for a newly fertilized egg and successful invasion into the uterine tissue, there is a requirement of finely balanced subsets of immune cells and their soluble mediators. Mainly genetics determine the developmental potential of the blastocyst. However, the optimal environment of the uterus determines the viability and competence of the blastocyst to become a fully developed fetus and on-time delivery achievements which in turn reflects the maternal immune response quality.

It has been claimed that pregnancy is a state of mild immunosuppression due to the reduction in the helper T-cell type 1 cell mediated response or decrease in natural killer cells. Sillman and Sedlis in the year 1987 reported that a higher incidence of cervical neoplasia is found in immunosuppressed women [15]. A steroidal hormone receptor binding element present on the transcriptional promotor of HPV-16 as reported by Gloss et al. is responsible for promotion of HPV transcription which suggests an involvement of hormonal activation of replication of HPV [21]. Observation from various studies indicated that the temporary altered immunity state and the increased steroidal hormonal levels during pregnancy might have an influence of the subsequence progression of the disease development effecting on HPV replication [16].

Fetus inherits 50% genome from the father that leads to the expressing of antigens which are acknowledged as foreign by the maternal immune system. To accommodate the semi-allogeneic fetus within the immunocompetent mother's body a range of complex processes take place [22]. The physiological and immunological

changes during pregnancy marks it a unique condition that makes the mother and the fetus more susceptible to certain infectious diseases, risk of congenital anomalies and the risk of more serious outcomes in other diseases. These changes are mainly driven by the cytokines, hormones and immune cells that lead to the modification of the immune system as well as the structural changes by remodeling of the endometrium [23]. In the 1950s, it was initially proposed that the induction of general immunosuppression during pregnancy allows the tolerance of the semi-allogeneic fetus and since then several hypotheses has been proposed explaining the reason why the fetus is not rejected by the maternal immune system (**Figure 1**).

On the contrary, after the natural infection pregnant women are capable of inducing immune responses and immune memory which is similar to non-pregnant women which proves the above hypothesis wrong [24]. Various studies have reported that the modulation of the immune system rather than active suppression is observed during pregnancy. Over the course of pregnancy, the progressive increase of the concentrations of steroidal hormones such as progesterone and estrogens induce a shift in the balance of pro and anti-inflammatory responses. During the first trimester of pregnancy which is called “open wound phase” the pro-inflammatory responses are prominent and in the second and the third trimester phases where the body prepared for deliver the anti-inflammatory responses are prominent [22]. Thus, it is clear that why the severity of certain diseases such as multiple sclerosis, rheumatoid arthritis induced by the inflammatory responses are often gets reduced during the third trimester of pregnancy and diseases which are controlled by the inflammatory responses such as malaria, influenza and lupus are increased during this phase [25]. There is a shift from Th1, which is oriented towards cell-mediated immunity, towards Th2, which is oriented towards the humoral immunity, responses is observed which is associated with an alteration of the balance between type1 and type 2T helper cells and this transition is needed for the development of a healthy fetus. The suppression of cytotoxic T lymphocytes and stimulation of B lymphocytes to further increase the production of antibodies that are potential to be transferred to the fetus is controlled by these Th2-skewed responses. The findings of Mor et al. [22] and Chaouat et al. [24] suggested that the placenta is capable of interaction and response to pathogens which makes it an active immunological site. At the feto-maternal interphase, the immune mechanisms contribute to protect the fetus from rejection providing required cytokines and growth factors for implantation of the fetus in the




Figure 1.
Accommodation of the semi-allogenic fetus in the maternal system.

placenta. The placenta can generate signals which may modulate the responses of the maternal immune system to pathogens which leads to a new paradigm that there is a combination of signals and responses originating both from the feto-placental unit and the maternal immune system which decides the overall immunological responses during pregnancy (Figure 2) [26].

3.2 Anatomical changes during pregnancy

The increased susceptibility to infection of pregnant women during pregnancy may be due to the immunological and anatomical changes of the uterine canal. Like other human viruses, the placenta or the cells of the fetal origin may get infected by HPV. The presence of HPV has been reported in the polymorphonuclear cells which suggest that the passage of virus through feto-maternal barrier may be allowed by the transfer of the maternal cells [27]. It has also been reported that the trophoblast cells are broadly permissive *in vitro* for HPV and within the trophoblast cell cultures this virus is able to complete its life cycle [28, 29].

In the uterine mucosa, especially in the postovulatory phase there is an increase in the circulating progesterone levels which initiates a cascade of molecular and cellular events that allows the initial anchor of the embryo to the epithelial layer of the endometrial surface further leading to the coordination of the invasion of the extra-embryonic trophoblast lineages. The proliferative activity of estrogen-primed endometrium is inhibited by progesterone which induces the secretory activity in the glandular compartment followed by triggering the influx of specialized uterine natural killer cells such as uNK; CD16/CD56bright in response to the production of local chemokines such as CXCL9, CCL4 and CXCL10. The Uterine natural killer (uNK) cells which are a rich source of angiogenic and growth factors, has been reported to have critical role in remodeling of the endometrial spiral arteries during and prior to pregnancy [5, 30]. The contractile activity of the myocytes of the junctional zone is strongly reduced by the progesterone which is a crucial process for the apposition of the blastocyst to the luminal epithelium. The most outstanding aspect of the maternal response during pregnancy is the transformation of the endometrial stromal fibroblasts into epithelioid-like, secretory decidual cells.

Upon implantation of a blastocyst, decidualization of the stromal compartment is observed in most species. On the other hand, in humans decidualization is initiated without the involvement of a pregnancy in the midsecretory phase of the cycle. It is progressive process which is at first initiated around the terminal spiral arteries




Figure 2.
HPV clearance and non-clearance during pregnancy and postpartum.

of the superficial endometrial layer which continues in pregnancy involving the entire endometrium as the pregnancy progresses [23]. The invasive or extravillous trophoblastic cells mediate the attachment of the placenta to the maternal uterine wall and they are responsible for the establishment of a low-resistance, high-flow supply of the maternal circulation to the fetus and the placenta. The placental dysfunction occurs due to the failed invasion of the extravillous trophoblast cells leading to the adverse obstetric outcomes such as spontaneous preterm delivery and pre-eclampsia. There are controversial reports on the HPV infection of the invasive trophoblast cells and their effects. There are reports showing the evidence of detection of HPV in trophoblast tissue from early pregnancy losses where HPV was more prominently found in spontaneous abortion cases than in cases of elective terminations of pregnancy. The genomes of the four different HPV types such as 11, 18, 16 and 31 are reported to undergo complete life cycle in 3A trophoblast cell lines and the HPV-31 in an in vitro system are shown to decrease cell number of the trophoblast cell and their adhesion [31].

Impaired placental function is associated with pregnancy loss or complications such as abruption, fetal growth restriction and pre-eclampsia. In this case we have to consider that the uterine remodeling during pregnancy is required to accommodate deep trophoblast invasion and the decidual process is not primarily under the embryonic control which makes the implantation process more vulnerable to perturbations in the mother [23].

4. The possible mechanisms responsible for self-clearance and non-clearance of HPV in pregnant women

4.1 Role of maternal immunity

Between the maternal decidua and the blastocyst the first point of contact is represented by the trophoblast. It has been reported by current studies that the trophoblast plays an active role during implantation and early placentation in shaping the immunological milieu by educating and attracting immune cells at the implantation site and thus modeling the subsequent response of the immune cells to external stimuli. Cytokines such as transforming growth factor- β (TGF β), CXCL12 which is also known as SDF1, CXCL8 which is also known as IL-8 and CCL2 which is also known as MCP1 are constitutively secreted by trophoblast cells. The secretion of these cytokines by trophoblast cells upon establishment at the implantation site, promotes the recruitment of neutrophils, peripheral monocytes, T cells, NK cells and Treg cells [32]. After decidualization although immune infiltrates are already present, studies have shown that for successful pregnancy, immune cell trafficking is crucial and any disruption in these chemokines signaling pathways leads to reduced infiltration of the immune cells and adverse pregnancy outcomes. Cytokines are also secreted by trophoblast cells that can act on immune cells after their recruitment. These secreted cytokines have been reported to stimulate the unique differentiation of the earlier recruited immune cells in such a way that they acquire phenotypes which are collectively essential for the successful pregnancy [33].

Decidual NK cells are less cytotoxic, thus they are different from peripheral NK cells and TGF β 12 and trophoblast-derived IL-15 induces this type of phenotypes. Decidual vascular remodeling which is crucial for development of the placenta targeted by these specialized NK cells [34]. CD14⁺ monocytes upon recruitment to the maternal-fetal interface acquire a unique phenotype that is M2-like macrophage which might be induced by the trophoblast-derived macrophage colony-stimulating

factor (M-CSF) and IL-10 [2118]. These M2-like macrophages participate in clearance of apoptotic cells and phagocytosis of degraded extracellular matrix and play a crucial role in tissue remodeling [35]. Trophoblast-educated M2 like macrophages on the contrary to other tissue-resident macrophages, maintain their CD14 expression and capable of immunomodulatory cytokine secretions such as type I interferons and TGF β [35]. Trophoblast-derived TGF β furthermore is able to induce the naive CD4+ cell differentiation into FOXP3+ Treg cells [36]. In addition to the trophoblast cells, a substantial amount of data have shown that the decidual cells also have vital role in regulation of the immune cell trafficking which is mostly T cells towards the site of implantation (**Figure 3**) [37, 38].

In addition to chemokines and cytokines secretion which attract and educate immune cells, numerous studies have shown that the trophoblast cells have the ability to sense and respond according to the microenvironment. Cell-surface receptors expressed by the trophoblast cells such as NOD-like receptors (NLRs) and TLRs can recognize specific molecular patterns within the microenvironment. These receptors have also the ability to recognize DAMPs which are basically released from damaged tissues and dying cells as well as PAMPs (Pathogen-associated molecular patterns) from viruses, bacteria and other microorganisms and thus permit the trophoblast cells to sense and response to these signals [39, 40]. Thus, the placental and fetal development is supported by the trophoblast cells attracting and educating immune cells and responding to the signals within the microenvironment in a unique way such as decidual differentiation followed by trophoblast migration and invasion, angiogenesis and finally spiral artery remodeling [41].

4.2 How pregnancy responses to viral infections

During pregnancy the consequences of viral infection can vary being a benign asymptomatic event which is undetected mostly and it can either cause the occurrence of fetal congenital malformations or pregnancy loss [42]. Like bacteria, the TLRs and NLRs expressed by the immune cells as well as those expressed by the trophoblast cells can be engaged by the viruses. Viral replication as well as vertical transmission of a virus to the developing fetus from the mother can also controlled by the trophoblast cells [43, 44]. Commensal bacteria which are present at the




Figure 3.
Immune modulation during pregnancy at the fetomaternal interface.

feto-maternal interface can induce the secretion of IFN β by trophoblast cells which supports the decidual receptivity by exerting immunomodulatory effects. It has been reported that the antiviral responses can be exerted by the IFN β [45] and thus one of the molecular pathways that is type I IFN pathway is actively inhibited by the viruses as they establish as infection. Various studies in mouse model have demonstrated that by inhibiting IRF3 phosphorylating in the placenta, viral infection can decrease IFN β expression which leads to the decreased antiviral responses [46]. TLR4 induced responses are modified by viral infections to commensal bacteria leading to the conversion of pro-inflammatory from anti-inflammatory in nature [47]. The receptivity and tolerance at the feto-maternal interface is promoted by the IFN β which suggests that blunted response of IFN β secondary to viral infection is responsible for the detrimental pregnancy consequences. The reduced receptivity of the immune cells at the feto-maternal interface due to the loss of IFN β also reduces their capacity to control and respond to other microorganisms. Thus, the association of the overwhelming inflammation with pregnancy complications suggests that there may be an involvement of an undetected viral infection which can change the response pattern of the feto-maternal interface to commensal bacteria. This hypothesis has been supported by the study results of Cardenas et al. [48] using an animal model. In that study, pregnant C57BL/6 mice was infected with MHV68 on 8.5 embryonic day and a low dose of LPS subsequent administration on E15.5 day leads to a cytokine storm which was characterized by high levels of G-CSF, CXCL1, IL-8 and TNF which is associated with parturition, a reduced production of IFN β followed by preterm birth. These changes in the cytokine profile leading to preterm birth is not induced alone either by LPS treatment or MHV68 infection but by a 'double-hit hypothesis' proposed by Mor et al. [41] which suggests that how trophoblast cells respond to bacterial products are changed by a viral infection which abolishes the normal microbiota immunomodulatory effects. In response of the commensal microbiota, the trophoblastic cells in the absence of a viral infection secrete IFN β , whereas IFN β signaling is abolished in the presence of a viral infection leading to eradicate its immunomodulatory effects which in turn changes the response of the trophoblastic cells to commensal bacteria shifting IFN β response to a cytokine storm which promotes preterm birth. However, it has been reported that the inflammation and preterm labour is also promoted either by an increased response of IFN β or inhibition of the IFN β regulators [49]. Thus, the original milieu which has a setting of immune-tolerance, during viral infection, is shifted into a state of pro-inflammatory condition [41].

4.3 Role of feto-maternal cell trafficking

During pregnancy there is a bidirectional cell passage exists between fetus and mother which is called feto-maternal cell trafficking. It is known as fetal microchimerism when there is a presence of fetal cells in the maternal circulation and maternal microchimerism when the maternal cells are present in the fetal circulation. Georg Schmorl in the year 1893 first reported about fetal microchimerism after identifying the placental trophoblast cells in a mother who died due to eclampsia [50]. The persistence of fetal cells in the maternal circulation [51, 52] and other maternal organs such as liver, heart, kidney [52] and bone marrow [53] has been reported decades after pregnancy. In 1963, with the identification of the maternal platelets and leukocytes in the cord blood the maternal microchimerism was described for the first time [54]. In healthy, immunocompetent individuals these maternal cells have been found to circulate into adult life [55].

At 7 weeks of pregnancy the bidirectional trafficking of the cells begins and increases throughout the gestation steadily and peaks at parturition [56]. In normal pregnancies, maternal microchimerism and fetal microchimerism has been

reported to be 42 and 51% respectively at the time of delivery [57]. In human blood and tissues the detection of maternal-fetal microchimerism is done by in situ hybridization for identification of whole cells and the identification of the origin of the DNA whether it is from mother or the fetus is done by polymerase chain reaction (PCR) to identify Y-chromosome DNA sequences in mother [58]. As the Y chromosome is easier to distinguish it is used as a biomarker to detect microchimerism and it does not require the fetus to be male. However, male microchimerism has been reported to be found in a fifth of women with no birth of a male child. The possible reason of the phenomenon can be a vanished male twin; early miscarriage of a male embryo; transfer of male cell through the maternal circulation from an older sibling to a later pregnancy; or due to an unexplored possibility of transfer of male DNA into the maternal circulation during sexual intercourse [59]. In females, male fetal cells have reported to show increased antigenicity. As the fetus carries paternal genes among which some are expressed on the cell surface that may induce potent allogeneic responses the mother confronts an immunological challenge during pregnancy. However, in spite of the immunologic differences of the cells, the fetus does not get rejected frequently (**Figure 4**) [60].

In pregnancy, the maternal and fetal cell exchange is common. During gestation, placenta allows the fetal and maternal reciprocal transport of cells in a state of mutual tolerance which proves placenta is not an immunologically inert barrier. It is not necessary to continue a pregnancy and deliver a child to develop microchimerism. Up to 500,000 nucleated fetal cells can be delivered into the maternal circulation even early terminations from surgical abortion [61, 62]. The cellular movement across the placental barrier is controlled by the maternal, fetal, or/and placental signals rather than nonspecific leakiness. The involvements of integrin-dependent and VEGF pathways are associated with the trans-placental cell trafficking mechanism but the initiation of the processes by the exact molecular signals are yet unknown [63]. In case of preeclampsia, fetal surgery and pregnancy termination where there is a disruption of the feto-maternal interface, association of altered feto-maternal cell trafficking has been reported which suggests that the placenta has a role in the cell migration regulation. The altered microchimerism levels are also associated with histocompatibility differences which suggests that the cell trafficking and the survival of the trafficked cells is either promoted or hindered by the immune response between the fetus and the mother [64, 65]. During pregnancy, the biological role of the bidirectional movement of cells is unknown, although it has implications in the fetal immune system development [66]; repair of tissue in autoimmune disease [67–70] tolerance mechanisms during pregnancy [71]; immune surveillance




Figure 4.
Feto-maternal cell trafficking during pregnancy.

[72] and cancer [73]. It is also involved in the maintenance of balance between the tolerance [74] and immunologic priming [75] which can influence the occurrence of autoimmune disease and transplantation outcomes. The utility of the feto-maternal cell trafficking has been identified clinically in the prediction of pregnancy complications [76, 77] and in prenatal testing for aneuploidies [78].

The research on microchimerism is still in its infancy, more specifically on the fetomaternal microchimerism. In women with autoimmune diseases, the long-term existence of the fetal cells and its speculative role has not yet been studied well. It has been reported by some of the researchers that the microchimeric cell populations occur due to pregnancy may have stem cell like properties which have the potential to home in damaged tissues and organs and further differentiate as part of the maternal repair response [62].

5. How HPV affects the pregnancy outcomes

Merckx et al. [79] reported that children born to HPV-positive mothers are at a significantly higher risk of becoming HPV positive which further results in infantile genital and anal condyloma acuminatum and juvenile laryngeal papillomatosis. However, by the age of 6 months some HPV infections are almost cleared. Hence, the question regarding susceptibility of pregnant women to HPV infection and its prevalence as compared to non-pregnant women population are crucial to answer [16].

Various studies reported that spontaneous abortion occurs in up to 30% of all pregnancies and it constitutes one of the most frequently occurring adverse pregnancy outcomes worldwide. In 5–13% of deliveries, spontaneous preterm birth is also observed [80]. As per the reports of recent investigations, the human papillomavirus infection of the placenta may be involved with placental abnormalities, spontaneous preterm delivery and spontaneous abortion.

Trophoblast cells as discussed earlier constitute the prime target for HPV in placenta which is responsible for placentation abnormality. Various studies showed that in pregnant women the prevalence of HPV infection ranges widely from 6 to 65% and the HPV DNA has been detected in amniotic fluid, placenta, fetal membranes and umbilical cord blood [81].

Delivery before 37 weeks of gestation is defined as preterm birth and it is an important complication worldwide for both multifetal and singleton pregnancies. As compared to children born at term, the preterm children are more likely to develop long-term neurological and developmental disorders and are at an increased risk of mortality. The highest rates of preterm delivery have been reported to be found in South-eastern and South Asia with a percentage of 13.4%. Especially in low-income countries, the morbidity and mortality are highest among these preterm children [80].

As per the fetal origin of adult disease (FOAD) hypothesis, the specific changes in the fetus are caused by the intrauterine environmental exposures which lead to the risk of developing diseases in adult life. Depending on the environmental interaction, these risks may lead to adult diseases. Coronary heart disease was documented earlier to support this hypothesis [82] but a range of chronic conditions has also now been included to expand the framework [83]. While, the 'thrifty phenotype' hypothesis states that low birth weight babies should not be at high risk of non-insulin dependent diabetes development when they grow with a scarcity of food [84, 85] but growing up in an area of affluence of the same babies would increase the risk and hence the intrauterine exposure plays an important role in inheriting the harmful potential in interaction with exposures later. Thus, the

reformulated FOAD hypothesis included epigenetics and the life-course epidemiology as an important factor which includes social and physical exposures during gestation, adolescence, childhood, young adulthood and adult life. To understand the development of chronic diseases, history specific and inter-generational elements of individual's life is also important [86]. The timing of exposure variables and how the outcome of interest is related to each other is the basis of life-course perspective. Hence, the effects of intrauterine exposures can be modified by the entire lifespan of an individual through the life-events, behavioral, biological and socioeconomic processes [87].

Infection with HPV (Human papillomavirus) is generally regarded as sexually transmitted disease. However, the detection of HPV in the oral mucosa of newborn babies who are sexually inexperienced has been reported in various studies which suggests plausible non-sexual alternative route of HPV infection. Detection of HPV genotypes and their similarities in the offspring's oral sample and in mother's genital tract suggests that the probable source of HPV infection in the newborn is the HPV infected mother. In the mother-baby pair, the reported vertical transmission rates are between 18.2 and 53.3% [88].

The possible mode of vertical transmission of HPV to infant from a mother is still under debate. However, during fertilization, or pregnancy or delivery the possible mode of transmission has been implicated. Evidence of prenatal transmission of HPV has been provided by Koskimaa et al. [89] and the presence of HPV in cord blood and placenta has been shown to increase the risk of carrying HPV DNA in the oral mucosa which suggests that in the transmission of HPV, unlike several other human viruses, placenta may play an important role [27]. Recent studies reported that the placenta and the maternal microbiomes have role in regulating the neonatal microbiomes which suggests during pregnancy the fetal exposure of microbiota has long-term outcomes in their health [90]. The translocated maternal oral microbes are presented to the fetal immune system at the placenta which acts as a site leading to the development of prenatal tolerance to the maternal microbiome [91].

The encounter with HPV and its significance in pre or perinatal period is not clear. Early exposure of HPV might have a significant impact in the HPV-specific immunity development, subsequent HPV infection and progression due to the immaturity of the immune system of the fetus and infant [92]. However, practically in children the HPV-specific immunity has remained an unknown area. As reported by Koskimaa et al. [88] and Koskimaa et al. [93], children aged 12–14 years had immunoreactivity specific to HPV 16 E2-, E6-, and E7. Whereas, various studies reported that the HPV-16 specific cell mediated immunity is much lower in adults [94, 95]. Between HPV positive and negative subjects, differences have been found in the memory Th cell (T Helper) reactivity against HPV16 E2, E7 and E6 oncoproteins in adults. Against HPV16 E2 and E6, the Th responsiveness is accompanied by the type 1 and type 2 cytokine secretions in a mixed pattern and seems to be more common in healthy individuals as compared to individuals with HPV16 induced disease.

Koskimaa et al. [89] reported that children those are exposed to HPV via cord blood or Oral HPV or placenta might have HPV16 specific T helper cell responses similar to the adults having HPV induced lesions which are highly different from negative HPV controls.

Though some studies have reported HPV infection to be associated with spontaneous preterm delivery and spontaneous abortion, controversy continues in this field due to the reason that some studies were unable to confirm this association.

6. Potential of HPV infection during pregnancy can lead to the development of cervical cancer and therapeutic strategies

Cervical cancer ranks as the 3rd most frequently diagnosed cancer with an estimated 569,847 incident cases and 311,365 deaths reported in the year 2018 (GLOBOCAN) worldwide and in women it is the fourth leading cause of death due to cancer. After breast cancer it ranks second in incidence and mortality rates in lower HDI settings. Worldwide in 28 countries it is the mostly diagnosed cancer and leading cause of cancer death in 42 countries which includes vast majority in South-Eastern Asia and Sub-Saharan Africa [96]. It has been reported that around 530,000 women get affected every year by cervical cancer and the HPV related cancer burden in women worldwide add up to 6% of total cancer cases.

In India, the diagnosis of new cervical cancer is about 96,922 cases annually making it the 2nd leading cause of female cancer. Women aged between 15 and 44 years, cervical cancer is the second most common female cancer in India [97].

The development of cervical cancer and its precursor lesions are reported through several epidemiological and biological studies to be associated with high-risk Human papillomavirus (HPV) infection. The development of high grade cervical lesions is reported to be associated with positive high-risk HPV test results in women with or without abnormal cervical smears [66, 98–100]. It has been reported in various studies on immunocompromised patients such as transplant recipients and AIDs patients that the increased persistence of high-risk HPV and HPV-mediated carcinogenesis is associated with compromised immunosurveillance [101, 102]. In pregnancy, the immune-response is altered in women and some studies concluded that there is no effect of pregnancy on CIN [103], whereas few reported high relapse rates of cervical dysplasia in the postpartum period [104]. Likewise, few studies reported high-risk HPV prevalence rate to be higher in pregnant women and others reported there is no difference of HPV prevalence between non-pregnant and pregnant women. However, on the natural course of high-risk HPV types infection the influence of pregnancy is not yet known. There are few questions need to be answered in this area: (1) what is the difference between the clearance of HPV in pregnant and non-pregnant women? (2) During pregnancy how does the high-risk HPV rate change? [6].

The Food and Drug Administration (FDA) has approved three vaccines such as the first-generation Human papillomavirus (HPV) vaccines, Gardasil (Merck, Kenilworth, NJ, USA) which is a quadri valent vaccine; Cervarix (GlaxoSmithKline, London, UK) which is a bivalent vaccine, have the potential to prevent about 70 and 84% of the cervical cancer cases respectively. Gardasil 9 (Merck), which is a next-generation nonavalent HPV vaccine, can prevent cervical cancer approximately 90%. However, pre-existing infections and their related cervical abnormalities cannot be treated by these vaccines. The American Society of Clinical Oncology (ASCO) in the year 2016 released cervical screening guidelines which recommend the screening for women aged between 30 and 49 years, one to three times in a lifetime in lower resource settings [105]. The screening should be done with primary HPV testing via the use of self-collected specimens as it has been reported to be more effective, adaptable and reliable method of screening as compared to traditional cytological methods and thus the effective cervical cancer screening can be done in several generations of women [106].

In terms of HPV vaccination and coverage rates of cervical screening, considerable inconsistencies exist worldwide between countries and within countries. In low-income and middle-income countries (LMICs), in the year 2008 the reported overall screening uptake was 19%, while in high-income regions it was 63% [107].

As compared to high-income countries, in low-income and middle-income countries the HPV vaccination coverage is much lower. In the high-income countries an estimated 33.6% of girls and women aged between 10 and 20 years had received the full course of HPV vaccine by the year 2014 as compared to low-income and middle-income countries which was 2.7% of the same age group of females [108]. Though studies are still in progress on the long-term vaccine efficacies to understand the total duration of protection, it has been reported that with Gardasil the protection against targeted HPV types last for at least 10 years [109], with Cervarix at least 9 years [110] and with Gardasil 9 at least 6 years [111]. But these vaccines have not sufficiently been tested during pregnancy and hence it is not used in pregnant women.

The Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for women having either an HPV infection or an abnormal Pap test or both if they are in the appropriate age group as that may protect them against the high-risk HPV types which have not been acquired by them. However, the vaccination has not the potential to treat the abnormal results of the Pap test or cure the current HPV infections [112]. Though, the vaccines have been reported to be safe when given to people with pre-existing HPV infection, it gives maximum benefit if given to people before being sexually active [113, 114]. However, some residual benefit from the vaccination will still be there for people already exposed to HPV even though infections with one or more HPV types which are included in the vaccines. Currently, there is no specific test available to detect past exposure of HPV in individuals and the approved HPV tests detect only current infection with high-risk HPV types at the cervix region without any information on past infection.

Even after the vaccination, the screening for cervical cancer need to be done as all HPV types which has the potential to cause cancer are not covered by the HPV vaccines. Therefore, in cervical cells to detect precancerous changes before the development of cancer, screening is essential. Additionally, women with existing HPV infection or who are not vaccinated the cervical screening is critically important. However, the screening recommendations may be changed in future for women given HPV vaccination.

Research works are in progress to develop therapeutic HPV vaccines which would prevent cancer development among women with previous history of HPV infection. The immune system will be stimulated by these vaccines which will result in specifically targeting and killing infected cells. The safety and efficacy of a therapeutic DNA vaccine are being tested by ongoing clinical trials to treat HPV related cervical and vulvar lesions [115–117]. A combination of preventive and therapeutic vaccine would be an ideal strategy in this case.

Topical microbicides is another preventive strategy which is being explored. In various studies, carrageenan which is an extracted compound from seaweed widely used in foods and other products has been reported to inhibit infection with HPV. Clinical trial in healthy individuals with a gel containing carrageenan is underway to test its efficacy to prevent genital HPV infections.

6.1 Immunization of the pregnant women

The response of the adaptive immune system of the infants cannot be protective to many pathogens in the first months of life. The T cells of both fetal and neonatal origin are skewed towards Th2 responses which are ineffective against intracellular pathogens. Ineffectiveness has also been reported for bacterial polysaccharides by antibody responses. Infants rely on additional protection during this period which is acquired from maternal antibodies during gestation passively transported through the placenta. At the time of birth, the antibody levels present in the infants

are correlated with the maternal antibody levels and the therefore, there is an interconnection between the antibody levels present in the maternal circulation and the degree of transfer of antibodies. However, the suboptimal maternal specific antibodies may not be sufficient to provide full protective immunity or can provide protection only for a limited period of time to the infants. Moreover, the maternal antibody levels decrease over a periods of approximately 6 months after birth. Therefore, the aim of the maternal immunization is to increase the concentration of maternal specific antibody and their passive transport to the fetus which will reduce the window of vulnerability for infants. IgG (Immunoglobulin G) is the only isotype among the five antibody classes that has the ability to efficiently cross the human placenta. Syncytiotrophoblast cells of the placenta, are responsible for the transfer of the IgG antibodies from mother to the fetus, which are located in contact with the maternal blood. In the circulation maternal IgG are internalized in endosomes and bind to Fc receptors (FcRn) of the neonatal cells which are expressed on the surface of the internal endosomes. On membrane of the fetal side of the syncytiotrophoblasts, the endosomes fuse and the IgG are released from FcRn. Passing through the villous stroma and fetal capillary endothelium, IgG enters the fetal circulation through an unknown mechanism. With the largest transferred proportion during the third trimester of pregnancy, the transfer of IgG through placenta increases over time especially within the last 4 weeks. Consistent with an active transport process, the IgG concentration in the fetal circulation are generally greater than the maternal circulation at full term of pregnancy [118, 119]. This transfer is influenced by several factors such as maternal non-infectious diseases, placental integrity, total maternal IgG concentration, FcRn availability, IgG subtype, timing of infection or vaccination and nature of the antigen [120]. IgG4, IgG3 and IgG2 are the least efficiently transferred to the fetus as compared to IgG1 which is the most efficiently transferred antibody subtype to the fetus.

Approximately after 2 weeks of maternal immunization, the concentration of specific antibodies starts increasing which suggests that if the vaccination is provided between 28 and 32 weeks of pregnancy, the optimal amount of specific IgG may be achieved in full-term infants at birth, but may not be the same for preterm infants. Diphtheria toxoid-acellular pertussis vaccine (Tdap) in the second trimester is reported to be reduced by the vaccination with tetanus toxoid which results in higher neonatal anti-pertussis antibody titers as compared to vaccination in the third trimester both in preterm and term neonates [121, 122]. The total longer transfer time may be a reason for the accumulation of antibodies in the fetal circulation. In addition to the maternal IgG antibodies which is transferred through placenta and known for providing protection, lesser concentration of IgG, IgM and high concentration of maternal IgA are also excreted in the breast milk and colostrum [123]. Immediately after delivery or in the second or third trimester of pregnancy, vaccination with Tdap reported to increase the pertussis-specific IgA antibody levels in the breast milk [124]. Therefore, another mode of transferring antibodies to the new born is breastfeeding. The maternal IgA transferred through the breast milk helps protecting the infants against enteric infections and respiratory illness with fever in infants born to influenza-vaccinated mothers for at least 6 months after birth [42, 123]. Though, there are evidences highlighting the maternal immunization benefits, few studies have also shown controversial interferences between the maternal IgG antibodies and the infant antibody responses [125].

The “immunological blunting”, a phenomenon is observed after the primary vaccination series in early infancy when the maternal IgG antibodies can inhibit the immune responses against the same or related antigens. While after the booster dose, this blunting effect dissipates [119, 126]. Blunting has been reported to be observed with polio and measles vaccines after natural infection or maternal

immunization for maternal antibodies [119, 127]. Though, the clinical importance of this blunting effect is unknown, the epidemiological data of implemented maternal immunization from various countries have not shown any negative impact on the protection against the diseases targeted [26, 128].

6.2 HPV vaccination during pregnancy

Gardasil and Cervarix both HPV vaccines are recombinant which contains virus-like particles (VLP's) and enhanced by an adjuvant which is responsible for triggering an immune response higher than a natural infection [129]. Gardasil 9, a 9-valent HPV vaccine was only licensed for use in the USA in December 2014.

Depending on age, full coverage by the HPV vaccine is obtained by 2 or 3 doses with the first dose administered at time 0, followed by the second dose after 1–2 months and the third dose after 6 months [130]. While, all doses are not received by many girls [131]. In order to achieve long-term duration of immunity, the repeat doses of vaccine are given which boost the immune system.

Worldwide, millions of doses of HPV vaccine since its introduction have been administered and involuntary administration also occurs during pregnancy as the young fertile women are the main recipients of the vaccines. Potentially harmful adverse effects (AE) to the unborn child such as preterm birth, miscarriage, congenital malformations, fetal death or fears of teratogenicity raise concern among both the health care providers and recipients. The development of sensitive organs such as the heart, the central nervous system takes place in the first trimester of pregnancy and in this period the environmental factors like medications and drugs theoretically might cause damage the developing fetus which is the main reason of concern. The vaccine manufacturers (Merck and GlaxoSmithKline) and the World Health Organization recommend avoiding HPV vaccination during pregnancy [36]. However, in case of accidental vaccination of pregnant women there are no interventions and no mandatory pregnancy testing before vaccination recommended so far. Moreover, conducting studies to investigate the pregnancy outcomes by administering HPV vaccines to pregnant women are not ethically feasible. In pregnancy, the true safety of the HPV vaccination has not yet been established through randomized controlled trial. Hence, the HPV vaccine administration to the pregnant women has not yet been approved [132].

7. Conclusion

In pregnant women, many observational studies reported the HPV infection risk but there are controversial results too. Higher HPV prevalence has been reported in few studies, whereas several studies reported lower prevalence in pregnant women or there is no statistical difference between pregnant and age matched non-pregnant controls [16].

For a successful pregnancy, a modulated, dynamic and responsive immune system is required but definitely not a suppressive one and this has been supported by an increasing number of studies. At the feto-maternal interface, the trophoblastic cells are important for the receptive immune system establishment which is achieved as a part of response mechanism to the normal microbiota which highlights the complexity of the regulatory pathways involved during pregnancy. Moreover, there are evidences on the effects that changed the modulated immune system and the receptive feto-maternal interface by a clinically silent viral infection emphasizes the necessity of better detection, treatment and prevention of the viral infections during pregnancy. This will further lead not only to the better outcomes

of pregnancy but also the postnatal development can be affected in a better way as these viral infections and the subsequent inflammations reported to be associated with mental health issues and diseases of the immune system such as asthma and allergies. The effects of viral infections on fetal development during pregnancy can more be exemplified by the recent Zika virus outbreak and its teratogenic effect on the development of brain [22]. Therefore, it is important to understand the complex immune responses during pregnancy, with the continued risk of pandemics and the emergence of newer diseases associated as secondary to the viral infection, which will lead to the development of appropriate approaches and tools to protect both the fetus and the mother [41].

Moreover, there are very limited data available due to the very limited number of investigations have been performed on materials from spontaneous abortions and spontaneous preterm deliveries due to HPV infection and the heterogeneous study groups making it difficult to come to a reliable conclusion. A proper study design, selection of proper controls is very essential in this case and a strict control of the similarity in patients/samples is needed for a valuable comparison between studies. Furthermore, the simple detection of a virus cannot be a real causative role for diseases in general or adverse pregnancy outcomes. Therefore, for this particular situation it is important to study the cellular localization and the viral activity to come to a realistic conclusion.

Therefore, we recommend more investigations on materials of adverse pregnancy outcomes including spontaneous abortion and spontaneous preterm delivery and the molecular mechanism of HPV infections on it which is the need of the hour and researchers need to conduct new studies to clarify the exact molecular mechanisms involved on the HPV infection in early pregnancy and how the self-clearance takes place during the course of pregnancy.

Conflict of interest

The authors declare no conflict of interest.

Author details

Sanchita Roy Pradhan, Sutapa Mahata, Dipanwita Ghosh, Pranab Kumar Sahoo, Sinjini Sarkar, Ranita Pal and Vilas D. Nasare*
Department of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, Kolkata, India

*Address all correspondence to: vilas.dr@gmail.com

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Trottier H, Mayrand MH, Baggio ML, Galan L, Ferenczy A, Villa LL, et al. Ludwig-McGill cohort study group. Risk of human papillomavirus (HPV) infection and cervical Neoplasia after pregnancy. *BMC Pregnancy and Childbirth*. 2015;**15**:244. DOI: 10.1186/s12884-015-0675-0
- [2] Mor G. Placental inflammatory response to Zika virus may affect fetal brain development. *American Journal of Reproductive Immunology*. 2016;**75**(4):421-422. DOI: 10.1111/aji.12505
- [3] Laskarin G, Kämmerer U, Rukavina D, Thomson AW, Fernandez N, Blois SM. Antigen-presenting cells and materno-fetal tolerance: An emerging role for dendritic cells. *American Journal of Reproductive Immunology*. 2007;**58**(3):255-267
- [4] Moffett-King A. Natural killer cells and pregnancy. *Nature Reviews Immunology*. 2002;**2**(9):656-663. Review. Erratum in: *Nature Reviews Immunology*. 2002;**2**(12):975
- [5] Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nature Medicine*. 2006;**12**(9):1065-1074
- [6] Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Bezemer PD, Voorhorst FJ, et al. High-risk human papillomavirus clearance in pregnant women: Trends for lower clearance during pregnancy with a catch-up postpartum. *British Journal of Cancer*. 2002;**87**(1):75-80
- [7] Jalil EM, Bastos FI, Melli PP, Duarte G, Simoes RT, Yamamoto AY, et al. HPV clearance in postpartum period of HIV-positive and negative women: A prospective follow-up study. *BMC Infectious Diseases*. 2013;**13**:564. DOI: 10.1186/1471-2334-13-564
- [8] Michelin D, Gissmann L, Street D, Potkul RK, Fisher S, Kaufmann AM, et al. Regulation of human papillomavirus type 18 in vivo: Effects of estrogen and progesterone in transgenic mice. *Gynecologic Oncology*. 1997;**66**(2):202-208
- [9] Yamasaki K, Miura K, Shimada T, Miura S, Abe S, Murakami M, et al. Epidemiology of human papillomavirus genotypes in pregnant Japanese women. *Journal of Human Genetics*. 2011;**56**(4):313-315. DOI: 10.1038/jhg.2011.11
- [10] Michaeli TF, Bergman Y, Gielchinsky Y. Rejuvenating effect of pregnancy on the mother. *Fertility and Sterility*. 2015;**103**(5):1125-1128
- [11] Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. *Vaccine*. 2008;**26**(Suppl 10):K1-K16. DOI: 10.1016/j.vaccine.2008.05.064
- [12] Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. *Public Health Genomics*. 2009;**12**(5-6):291-307. DOI: 10.1159/000214920
- [13] Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. *The Journal of Infectious Diseases*. 2010;**202**(12):1789-1799. DOI: 10.1086/657321

- [14] Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, et al. Human papillomavirus infection and reinfection in adult women: The role of sexual activity and natural immunity. *Cancer Research*. 2010;**70**(21):8569-8577. DOI: 10.1158/0008-5472.CAN-10-0621
- [15] Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. *The International Journal of Cancer*. 2016;**138**(10):2428-2438. DOI: 10.1002/ijc.29971
- [16] Liu P, Xu L, Sun Y, Wang Z. The prevalence and risk of human papillomavirus infection in pregnant women. *Epidemiology and Infection*. 2014;**142**(8):1567-1578. DOI: 10.1017/S0950268814000636
- [17] Castellsagué X, Drudis T, Cañadas MP, Goncé A, Ros R, Pérez JM, et al. Human papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: A prospective study in Spain. *BMC Infectious Diseases*. 2009;**9**:74. DOI: 10.1186/1471-2334-9-74
- [18] Niyibizi J, Zanré N, Mayrand MH, Trottier H. The association between adverse pregnancy outcomes and maternal human papillomavirus infection: A systematic review protocol. *Systematic Reviews*. 2017;**6**(1):53. DOI: 10.1186/s13643-017-0443-5
- [19] de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. *The Lancet Infectious Diseases*. 2007;**7**(7):453-459
- [20] Pandey D, Solleti V, Jain G, Das A, Shama Prasada K, Acharya S, et al. Human papillomavirus (HPV) infection in early pregnancy: Prevalence and implications. *Infectious Diseases in Obstetrics and Gynecology*. 2019;**2019**:4376902. DOI: 10.1155/2019/4376902
- [21] Gloss B, Bernard HU, Seedorf K, Klock G. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. *The EMBO Journal*. 1987;**6**(12):3735-3743
- [22] Mor G, Cardenas I. The immune system in pregnancy: A unique complexity. *American Journal of Reproductive Immunology*. 2010;**63**(6):425-433. DOI: 10.1111/j.1600-0897.2010.00836.x
- [23] Gellersen B, Brosens IA, Brosens JJ. Decidualization of the human endometrium: Mechanisms, functions, and clinical perspectives. *Seminars in Reproductive Medicine*. 2007;**25**(6):445-453
- [24] Chaouat G, Petitbarat M, Dubanchet S, Rahmati M, Ledée N. Tolerance to the foetal allograft? *American Journal of Reproductive Immunology*. 2010;**63**(6):624-636. DOI: 10.1111/j.1600-0897.2010.00832.x
- [25] Omer SB. Maternal immunization. *The New England Journal of Medicine*. 2017;**376**(13):1256-1267. DOI: 10.1056/NEJMra1509044
- [26] Vojtek I, Dieussaert I, Doherty TM, Franck V, Hanssens L, Miller J, et al. Maternal immunization: Where are we now and how to move forward? *Annals of Medicine*. 2018;**50**(3):193-208. DOI: 10.1080/07853890.2017.1421320
- [27] Younes AS, Csire M, Kapusinszky B, Szomor K, Takács M, Berencsi G.

- Heterogeneous pathways of maternal-fetal transmission of human viruses (review). *Pathology Oncology Research*. 2009;**15**(3):451-465. DOI: 10.1007/s12253-009-9166-9
- [28] You H, Liu Y, Agrawal N, Prasad CK, Chiriva-Internati M, Lowery CL, et al. Infection, replication, and cytopathology of human papillomavirus type 31 in trophoblasts. *Virology*. 2003;**316**(2):281-289
- [29] Freitas AC, Mariz FC, Silva MA, Jesus AL. Human papillomavirus vertical transmission: Review of current data. *Clinical Infectious Diseases*. 2013;**56**(10):1451-1456. DOI: 10.1093/cid/cit066
- [30] Croy BA, van den Heuvel MJ, Borzychowski AM, Tayade C. Uterine natural killer cells: A specialized differentiation regulated by ovarian hormones. *Immunological Reviews*. 2006;**214**:161-185
- [31] Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. *Human Reproduction*. 2008;**23**(3):709-715. DOI: 10.1093/humrep/dem404
- [32] Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Leirós CP, et al. Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells. *American Journal of Reproductive Immunology*. 2012;**67**(1):17-27. DOI: 10.1111/j.1600-0897.2011.01056.x. Epub Aug 7, 2011
- [33] Manaster I, Mizrahi S, Goldman-Wohl D, Sela HY, Stern-Ginossar N, Lankry D, et al. Endometrial NK cells are special immature cells that await pregnancy. *Journal of Immunology*. 2008;**181**(3):1869-1876
- [34] Zhang J, Chen Z, Smith GN, Croy BA. Natural killer cell-triggered vascular transformation: Maternal care before birth? *Cellular and Molecular Immunology*. 2011;**8**(1):1-11. DOI: 10.1038/cmi.2010.38
- [35] Houser BL, Tilburgs T, Hill J, Nicotra ML, Strominger JL. Two unique human decidual macrophage populations. *Journal of Immunology*. 2011;**186**(4):2633-2642. DOI: 10.4049/jimmunol.1003153
- [36] Pregnancy Guidelines and Recommendations by Vaccine | CDC [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html?CDC_AA_refVal=https://www.cdc.gov/vaccines/pregnancy/hcp/guidelines.html [Cited Oct 10, 2019]
- [37] Lockwood CJ, Huang SJ, Chen CP, Huang Y, Xu J, Faramarzi S, et al. Decidual cell regulation of natural killer cell-recruiting chemokines: Implications for the pathogenesis and prediction of preeclampsia. *The American Journal of Pathology*. 2013;**183**(3):841-856. DOI: 10.1016/j.ajpath.2013.05.029
- [38] Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. *Science*. 2012;**336**(6086):1317-1321. DOI: 10.1126/science.1220030
- [39] Abrahams VM, Visintin I, Aldo PB, Guller S, Romero R, Mor G. A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells. *Journal of Immunology*. 2005;**175**(12):8096-8104
- [40] Costello MJ, Joyce SK, Abrahams VM. NOD protein expression and function in first trimester trophoblast cells. *American Journal of Reproductive Immunology*. 2007;**57**(1):67-80

- [41] Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. *Nature Reviews. Immunology*. 2017;**17**(8):469-482. DOI: 10.1038/nri.2017.64
- [42] Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *American Journal of Reproductive Immunology*. 2015;**73**(3):199-213. DOI: 10.1111/aji.12355
- [43] Coyne CB, Lazear HM. Zika virus—reigniting the TORCH. *Nature Reviews. Microbiology*. 2016;**14**(11):707-715. DOI: 10.1038/nrmicro.2016.125
- [44] Giugliano S, Petroff MG, Warren BD, Jasti S, Linscheid C, Ward A, et al. Hepatitis C virus sensing by human Trophoblasts induces innate immune responses and recruitment of maternal NK cells: Potential implications for limiting vertical transmission. *Journal of Immunology*. 2015;**195**(8):3737-3747. DOI: 10.4049/jimmunol.1500409
- [45] Tian M, Zhang Y, Liu Z, Sun G, Mor G, Liao A. The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. *Scientific Reports*. 2016;**6**:27683. DOI: 10.1038/srep27683
- [46] Olivadoti M, Toth LA, Weinberg J, Opp MR. Murine gammaherpesvirus 68: A model for the study of Epstein-Barr virus infections and related diseases. *Comparative Medicine*. 2007;**57**(1):44-50
- [47] Racicot K, Kwon JY, Aldo P, Abrahams V, El-Guindy A, Romero R, et al. Type I interferon regulates the placental inflammatory response to bacteria and is targeted by virus: Mechanism of polymicrobial infection-induced preterm birth. *American Journal of Reproductive Immunology*. 2016;**75**(4):451-460. DOI: 10.1111/aji.12501
- [48] Cardenas I, Means RE, Aldo P, Koga K, Lang SM, Booth CJ, et al. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. *Journal of Immunology*. 2010;**185**(2):1248-1257. DOI: 10.4049/jimmunol.1000289
- [49] Cappelletti M, Presicce P, Lawson MJ, Chaturvedi V, Stankiewicz TE, Vanoni S, et al. Type I interferons regulate susceptibility to inflammation-induced preterm birth. *JCI Insight*. 2017;**2**(5):e91288. DOI: 10.1172/jci.insight.91288
- [50] Lapaire O, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Georg Schmorl on trophoblasts in the maternal circulation. *Placenta*. 2007;**28**(1):1-5. Epub Apr 18, 2006
- [51] Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;**93**(2):705-708
- [52] O'Donoghue K, Chan J, de la Fuente J, Kennea N, Sandison A, Anderson JR, et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. *Lancet*. 2004;**364**(9429):179-182
- [53] Koopmans M, Kremer Hovinga IC, Baelde HJ, Fernandes RJ, de Heer E, Bruijn JA, et al. Chimerism in kidneys, livers and hearts of normal women: Implications for transplantation studies. *American Journal of Transplantation*. 2005;**5**(6):1495-1502
- [54] Desai RG, Creger WP. Maternofetal passage of leukocytes and platelets in man. *Blood*. 1963;**21**:665-673
- [55] Maloney S, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, et al.

Microchimerism of maternal origin persists into adult life. *The Journal of Clinical Investigation*. 1999;**104**(1):41-47

[56] Ariga H, Ohto H, Busch MP, Imamura S, Watson R, Reed W, et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: Implications for noninvasive prenatal diagnosis. *Transfusion*. 2001;**41**(12):1524-1530

[57] Lo YM, Lo ES, Watson N, Noakes L, Sargent IL, Thilaganathan B, et al. Two-way cell traffic between mother and fetus: Biologic and clinical implications. *Blood*. 1996;**88**(11):4390-4395

[58] Jeanty C, Derderian SC, Mackenzie TC. Maternal-fetal cellular trafficking: Clinical implications and consequences. *Current Opinion in Pediatrics*. 2014;**26**(3):377-382. DOI: 10.1097/MOP.0000000000000087

[59] Yan Z, Lambert NC, Guthrie KA, Porter AJ, Loubiere LS, Madeleine MM, et al. Male microchimerism in women without sons: Quantitative assessment and correlation with pregnancy history. *The American Journal of Medicine*. 2005;**118**(8):899-906

[60] Tanaka A, Lindor K, Ansari A, Gershwin ME. Fetal microchimerisms in the mother: Immunologic implications. *Liver Transplantation*. 2000;**6**(2):138-143

[61] Bianchi DW, Fisk NM. Fetomaternal cell trafficking and the stem cell debate: Gender matters. *Journal of the American Medical Association*. 2007;**297**(13):1489-1491

[62] Knippen MA. Microchimerism: Sharing genes in illness and in health. *ISRN Nursing*. 2011;**2011**:893819. DOI: 10.5402/2011/893819

[63] Chen CP, Lee MY, Huang JP, Aplin JD, Wu YH, Hu CS, et al.

Trafficking of multipotent mesenchymal stromal cells from maternal circulation through the placenta involves vascular endothelial growth factor receptor-1 and integrins. *Stem Cells*. 2008;**26**(2):550-561

[64] Berry SM, Hassan SS, Russell E, Kukuruga D, Land S, Kaplan J. Association of maternal histocompatibility at class II HLA loci with maternal microchimerism in the fetus. *Pediatric Research*. 2004;**56**(1):73-78

[65] Lambert NC, Evans PC, Hashizumi TL, Maloney S, Gooley T, Furst DE, et al. Cutting edge: Persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: Implications in autoimmunity. *Journal of Immunology*. 2000;**164**(11):5545-5548

[66] Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. *International Journal of Cancer*. 1996;**68**(6):766-769

[67] Khosrotehrani K, Guegan S, Fraitag S, Oster M, de Prost Y, Bodemer C, et al. Presence of chimeric maternally derived keratinocytes in cutaneous inflammatory diseases of children: The example of pityriasis lichenoides. *The Journal of Investigative Dermatology*. 2006;**126**(2):345-348

[68] Khosrotehrani K, Johnson KL, Cha DH, Salomon RN, Bianchi DW. Transfer of fetal cells with multilineage potential to maternal tissue. *Journal of the American Medical Association*. 2004;**292**(1):75-80

[69] Stevens AM, Hermes HM, Rutledge JC, Buyon JP, Nelson JL. Myocardial-tissue-specific phenotype of

maternal microchimerism in neonatal lupus congenital heart block. *Lancet*. 2003;**362**(9396):1617-1623

[70] Vanzyl B, Planas R, Ye Y, Foulis A, de Krijger RR, Vives-Pi M, et al. Why are levels of maternal microchimerism higher in type 1 diabetes pancreas? *Chimerism*. 2010;**1**(2):45-50. DOI: 10.4161/chim.1.2.13891

[71] Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. *Science*. 2008;**322**(5907):1562-1565. DOI: 10.1126/science.1164511

[72] Gadi VK, Nelson JL. Fetal microchimerism in women with breast cancer. *Cancer Research*. 2007;**67**(19):9035-9038

[73] Cirello V, Perrino M, Colombo C, Muzza M, Filopanti M, Vicentini L, et al. Fetal cell microchimerism in papillary thyroid cancer: Studies in peripheral blood and tissues. *International Journal of Cancer*. 2010;**126**(12):2874-2878. DOI: 10.1002/ijc.24993

[74] Dutta P, Molitor-Dart M, Bobadilla JL, Roenneburg DA, Yan Z, Torrealba JR, et al. Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. *Blood*. 2009;**114**(17):3578-3587. DOI: 10.1182/blood-2009-03-213561

[75] Opiela SJ, Levy RB, Adkins B. Murine neonates develop vigorous in vivo cytotoxic and Th1/Th2 responses upon exposure to low doses of NIMA-like alloantigens. *Blood*. 2008;**112**(4):1530-1538. DOI: 10.1182/blood-2007-08-106500

[76] Farina A, Sekizawa A, Sugito Y, Iwasaki M, Jimbo M, Saito H, et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate

in low-risk nonsymptomatic patients. *Prenatal Diagnosis*. 2004;**24**(2):83-86

[77] Jakobsen TR, Clausen FB, Rode L, Dziegiel MH, Tabor A. High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery. *Prenatal Diagnosis*. 2012;**32**(9):840-845. DOI: 10.1002/pd.3917

[78] Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. *Clinical Chemistry*. 2014;**60**(1):243-250. DOI: 10.1373/clinchem.2013.207951

[79] Merckx M et al. Transmission of carcinogenic human papillomavirus types from mother to child: A metaanalysis of published studies. *European Journal of Cancer Prevention*. 2012

[80] Koullali B, Oudijk MA, Nijman TA, Mol BW, Pajkrt E. Risk assessment and management to prevent preterm birth. *Seminars in Fetal and Neonatal Medicine*. 2016;**21**(2):80-88. DOI: 10.1016/j.siny.2016.01.005

[81] Ambühl LM, Baandrup U, Dybkær K, Blaakær J, Uldbjerg N, Sørensen S. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery. *Infectious Diseases in Obstetrics and Gynecology*. 2016;**2016**:3086036. DOI: 10.1155/2016/3086036

[82] Barker DJ. Fetal origins of coronary heart disease. *BMJ*. 1995;**311**(6998):171-174

[83] Barker DJP. Fetal and infant origins of adult disease. *Monatsschrift Kinderheilkunde*. 2001;**149**(Suppl. 1): S2-S6. DOI: 10.1007/s001120170002

[84] Bateson P, Barker D, Clutton-Brock T, Deb D, D'Udine B, Foley RA, et al. Developmental plasticity

and human health. *Nature*. 2004;**430**(6998):419-421

[85] Hales CN, Barker DJ. The thrifty phenotype hypothesis. *British Medical Bulletin*. 2001;**60**:5-20

[86] Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: Conceptual models, empirical challenges and interdisciplinary perspectives. *International Journal of Epidemiology*. 2002;**31**(2):285-293

[87] Skogen JC, Overland S. The fetal origins of adult disease: A narrative review of the epidemiological literature. *JRSM Short Reports*. 2012;**3**(8):59. DOI: 10.1258/shorts.2012.012048

[88] Koskimaa HM, Paaso A, Welters MJ, Grénman S, Syrjänen K, van der Burg SH, et al. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. *Journal of Translational Medicine*. 2015;**13**:370. DOI: 10.1186/s12967-015-0733-4

[89] Koskimaa HM, Paaso A, Welters MJP, Grénman S, Syrjänen K, van der Burg SH, et al. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. *European Journal of Clinical Microbiology & Infectious Diseases*. 2017;**36**(8):1491-1503. DOI: 10.1007/s10096-017-2958-z

[90] Solt I. The human microbiome and the great obstetrical syndromes: A new frontier in maternal-fetal medicine. *Best Practice & Research. Clinical Obstetrics and Gynaecology*. 2015;**29**(2):165-175. DOI: 10.1016/j.bpobgyn.2014.04.024

[91] Zaura E, Nicu EA, Krom BP, Keijser BJ. Acquiring and maintaining a normal oral microbiome: Current perspective. *Frontiers in Cellular and*

Infection Microbiology. 2014;**4**:85. DOI: 10.3389/fcimb.2014.00085

[92] Gollwitzer ES, Marsland BJ. Impact of early-life exposures on immune maturation and susceptibility to disease. *Trends in Immunology*. 2015;**36**(11):684-696. DOI: 10.1016/j.it.2015.09.009

[93] Koskimaa HM, Paaso AE, Welters MJ, Grénman SE, Syrjänen KJ, van der Burg SH, et al. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish family HPV cohort. *Journal of Translational Medicine*. 2014;**12**:44. DOI: 10.1186/1479-5876-12-44

[94] Welters MJ, van der Logt P, van den Eeden SJ, Kwappenberg KM, Drijfhout JW, Fleuren GJ, et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. *International Journal of Cancer*. 2006;**118**(4):950-956

[95] Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, Kwappenberg KM, et al. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. *International Journal of Cancer*. 2010;**126**(1):133-141. DOI: 10.1002/ijc.24804

[96] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2018;**68**(6):394-424. DOI: 10.3322/caac.21492

[97] Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX,

de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019 [Accessed: Sep 15, 2019]

[98] Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. *Journal of the National Cancer Institute*. 1995;**87**(18):1365-1371

[99] Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. *Lancet*. 1999;**354**(9172):20-25. Erratum in: *Lancet*. 2015;**386**(10002):1446

[100] Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. *International Journal of Cancer*. 1995;**61**(3):306-311

[101] Petry KU, Köchel H, Bode U, Schedel I, Niesert S, Glaubitz M, et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. *Gynecologic Oncology*. 1996;**60**(1):30-34

[102] Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. *The New England Journal of Medicine*. 1997;**337**(19):1343-1349

[103] Jain AG, Higgins RV, Boyle MJ. Management of low-grade squamous

intraepithelial lesions during pregnancy. *American Journal of Obstetrics and Gynecology*. 1997;**177**(2):298-302

[104] Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. *Obstetrics and Gynecology*. 1999;**93**(3):359-362

[105] Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. *Journal of Global Oncology*. 2016;**3**(5):635-657. DOI: 10.1200/JGO.2016.006577

[106] Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: A modelling study. *The Lancet Oncology*. 2019;**20**(3):394-407. DOI: 10.1016/S1470-2045(18)30836-2

[107] Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. *PLoS Medicine*. 2008;**5**(6):e132. DOI: 10.1371/journal.pmed.0050132

[108] Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. *The Lancet Global Health*. 2016;**4**(7):e453-e463. DOI: 10.1016/S2214-109X(16)30099-7. Erratum in: *The Lancet Global Health*. 2017;**5**(7):e662

[109] Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M et al. A 12-year follow-up on the long-term effectiveness of the Quadrivalent human papillomavirus vaccine in 4 Nordic countries. *Clinical Infectious*

Diseases. 2018;**66**(3):339-345. DOI: 10.1093/cid/cix797

[110] Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. *Human Vaccines & Immunotherapeutics*. 2014;**10**(8):2147-2162. DOI: 10.4161/hv.29532

[111] Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: A randomised, double-blind trial. *Lancet*. 2017;**390**(10108):2143-2159. DOI: 10.1016/S0140-6736(17)31821-4

[112] Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommendations and Reports*. 2014;**63**(RR-05):1-30. Erratum in: *MMWR Recommendations and Reports*. 2014;**63**(49):1182

[113] Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. *American Journal of Obstetrics & Gynecology*. 2016;**215**(2):212.e1-212.e15. DOI: 10.1016/j.ajog.2016.02.021

[114] Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. *Journal*

of the American Medical Association. 2007;**298**(7):743-753

[115] Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2018;**47**:59-72. DOI: 10.1016/j.bpobgyn.2017.09.008

[116] Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. *Lancet*. 2015;**386**(10008):2078-2088. DOI: 10.1016/S0140-6736(15)00239-1

[117] Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. *Journal of Biomedical Science*. 2016;**23**(1):75

[118] Faucette AN, Unger BL, Gonik B, Chen K. Maternal vaccination: Moving the science forward. *Human Reproduction Update*. 2015;**21**(1):119-135. DOI: 10.1093/humupd/dmu041

[119] Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. *Clinical & Developmental Immunology*. 2012;**2012**:985646. DOI: 10.1155/2012/985646

[120] Chu HY, Englund JA. Maternal immunization. *Birth Defects Research*. 2017;**109**(5):379-386. DOI: 10.1002/bdra.23547

[121] Eberhardt CS, Blanchard-Rohner G, Lemaître B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant Seropositivity against pertussis. *Clinical Infectious Diseases*.

2016;**62**(7):829-836. DOI: 10.1093/cid/ciw027

[122] Eberhardt CS, Blanchard-Rohner G, Lemaître B, Combescure C, Othenin-Girard V, Chilin A, et al. Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. *Clinical Infectious Diseases*. 2017;**64**(8):1129-1132. DOI: 10.1093/cid/cix046

[123] Palmeira P, Carneiro-Sampaio M. Immunology of breast milk. *Revista da Associação Médica Brasileira* (1992). 2016;**62**(6):584-593. DOI: 10.1590/1806-9282.62.06.584

[124] De Schutter S, Maertens K, Baerts L, De Meester I, Van Damme P, Leuridan E. Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk: Comparison of different vaccination strategies in women. *The Pediatric Infectious Disease Journal*. 2015;**34**(6):e149-e152. DOI: 10.1097/INF.0000000000000675

[125] Niewiesk S. Maternal antibodies: Clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. *Frontiers in Immunology*. 2014;**5**:446. DOI: 10.3389/fimmu.2014.00446

[126] Maertens K, Caboré RN, Huygen K, Vermeiren S, Hens N, Van Damme P, et al. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. *Vaccine*. 2016;**34**(31):3613-3619. DOI: 10.1016/j.vaccine.2016.04.066

[127] Edwards KM. Maternal antibodies and infant immune responses to vaccines. *Vaccine*. 2015;**33**(47):6469-6472. DOI: 10.1016/j.vaccine.2015.07.085

[128] Amirthalingam G, Campbell H, Ribeiro S, Fry NK, Ramsay M, Miller E, et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. *Clinical Infectious Diseases*. 2016;**63**(suppl 4):S236-S243

[129] Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial. *Mayo Clinic Proceedings*. 2005;**80**(5):601-610

[130] Human Papillomavirus Vaccines: WHO Position Paper, October 2014 [Internet]. *Releve Epidemiologique Hebdomadaire*. U.S. National Library of Medicine. 2014. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/25346960> [Cited Oct 10, 2019]

[131] Liu G, Kong L, Du P. HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US. *Papillomavirus Research*. 2016;**2**:1-8

[132] Bonde U, Joergensen JS, Lamont RF, Mogensen O. Is HPV vaccination in pregnancy safe? *Human Vaccines & Immunotherapeutics*. 2016;**12**(8):1960-1964. Epub May 12, 2016